Narrow search
Showing 1 - 3 of 3
Cover Image
Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain
Blasco, Antonio J.; Lázaro, Pablo; Caballero, Teresa; … - In: Health economics review 3 (2013) 2, pp. 1-11
Background: Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe. Aim: To compare the economic impact of two icatibant administration strategies: health...
Persistent link: https://www.econbiz.de/10009755347
Cover Image
Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain
Blasco, Antonio J.; Lázaro, Pablo; Caballero, Teresa; … - In: Health economics review 3 (2013) 2, pp. 1-11
Background: Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe. Aim: To compare the economic impact of two icatibant administration strategies: health...
Persistent link: https://www.econbiz.de/10010148175
Cover Image
Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain
Blasco, Antonio; Lázaro, Pablo; Caballero, Teresa; … - In: Health Economics Review 3 (2013) 1, pp. 1-11
Costs related to the management of acute HAE attacks with C1 inhibitor deficiency may be substantially reduced through interventions targeting home treatment by training patients to self-administer icatibant. </AbstractSection> Copyright Blasco et al; licensee Springer. 2013
Persistent link: https://www.econbiz.de/10010998831